TG Therapeutics’ ublituximab tops Sanofi’s Aubagio in MS trial
19th April 2021
New York-headquartered biopharma company TG Therapeutics has revealed new data for its investigational therapy ublituximab, which demonstrated superiority over Sanofi’s Aubagio in patients with relapsing forms of multiple sclerosis (MS).
The data, from the Phase III ULTIMATE I & II studies, evaluated ublituximab – a novel glycoengineered anti-CD20 monoclonal antibody – in patients with RMS.
Both studies hit their primary endpoint, with ublituximab treatment demonstrating a statistically significant reduction in the annualised relapse rate (ARR) over a 96-week period compared to Aubagio (teriflunomide).
In the ULTIMATE I trial, ublituximab treatment resulted in an ARR of 0.076 compared to 0.188 for Aubagio – a relative reduction of approximately 60%.